APA (7th ed.) Citation

H, I., JG, v. O., JC, P., L, L., DR, B., JS, B., . . . SD, B. (2022). Preclinical and Pilot Study of Type I FLT3 Tyrosine Kinase Inhibitor, Crenolanib, with Sorafenib in Acute Myeloid Leukemia and FLT3-Internal Tandem Duplication. Clinical cancer research : an official journal of the American Association for Cancer Research, 28(12), 2536. https://doi.org/10.1158/1078-0432.CCR-21-4450

Chicago Style (17th ed.) Citation

H, Inaba, et al. "Preclinical and Pilot Study of Type I FLT3 Tyrosine Kinase Inhibitor, Crenolanib, with Sorafenib in Acute Myeloid Leukemia and FLT3-Internal Tandem Duplication." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 28, no. 12 (2022): 2536. https://doi.org/10.1158/1078-0432.CCR-21-4450.

MLA (9th ed.) Citation

H, Inaba, et al. "Preclinical and Pilot Study of Type I FLT3 Tyrosine Kinase Inhibitor, Crenolanib, with Sorafenib in Acute Myeloid Leukemia and FLT3-Internal Tandem Duplication." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 28, no. 12, 2022, p. 2536, https://doi.org/10.1158/1078-0432.CCR-21-4450.